fda warning letter glp-1 solution september 9 2025 Last month, the issued 25 letters to telehealth companies over what it called false or misleading claims about compounded medications. Read more at the link in the comments below Compounded Semaglutide & Tirzepatide 2025:

Note: This article focuses on injectable GLP-1s, which are the most commonly prescribed form for weight loss

9 This paper presents a detailed overview of the biomarker function of TMAO in the gut-organ axis, as well as the regulation mechanism of TMAO on the gut-organ axis, particularly in relation to the crosstalk mechanisms involved in cell death

10.7554/eLife.90854 6 BuchholzK.PutriantiE

Post hoc analysis of LEADER data revealed a persistent increase in the overall risk of biliary tract-related events and gallbladder diseases, consistently observed across four categories: uncomplicated gallbladder stones, complicated gallbladder stones, cholecystitis with/without gallbladder stones, and biliary obstruction [34]